Robert Whisnant
Urology · Roanoke, VANPI 1609863513
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $81,250 of the $83,880 with a category attached, or 96.9%. Roanoke Area Surgical Lasers, LLC accounts for 96.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $30,179 and has fallen 99.9% since, to $27 in 2025. Among urology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $559.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roanoke Area Surgical Lasers, LLC$81K
- Astellas Pharma US Inc$1K
- Pfizer$354
- Endo Pharmaceuticals Inc.$241
- Myovant Sciences Inc.$157
- Blue Earth Diagnostics$137
- plus $659 from 16 others
What the payments were for
- Food & beverage$2,4383%
- Education$1930%
- Ownership interest$81,25097%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roanoke Area Surgical Lasers, LLC | 4 | $81,250 |
| Astellas Pharma US Inc | 54 | $1,083 |
| Pfizer | 25 | $354 |
| Endo Pharmaceuticals Inc. | 15 | $241 |
| Myovant Sciences Inc. | 10 | $157 |
| Blue Earth Diagnostics | 6 | $137 |
| AbbVie(2 entities) | 5 | $109 |
| Urovant Sciences Inc | 5 | $81 |
| Sumitomo Pharma America, Inc. | 4 | $71 |
| KARL Storz Endoscopy-america | 2 | $70 |
| Olympus America Inc. | 3 | $55 |
| Bayer | 3 | $51 |
| Neotract Inc. | 2 | $40 |
| Photocure Inc | 2 | $33 |
| 180 Medical, Inc. | 1 | $27 |
| Coloplast | 2 | $26 |
| Teleflex LLC | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Urogen Pharma, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 2 | $14 |
| Johnson & Johnson | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
How this compares
$83,880 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 23 | $16,612 |
| Tamsulosin Hcl | 238 | $3,497 |
| Finasteride | 93 | $1,142 |
| Oxybutynin Chloride | 13 | $486 |
| Terazosin Hcl | 12 | $260 |
| Alendronate Sodium | 37 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,083 | $16,61223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.
Other urology in Roanoke
- Charles DanielRoanoke$94K
- David KageyRoanoke$90K
- Rodney PoffenbergerRoanoke$85K
- Mark SchmidtRoanoke$84K
- Yu ZhangRoanoke$34K
- Michael FabrizioVirginia Beach$1.5M
- Gregg EureVirginia Beach$1.4M
- Jessica DelongVirginia Beach$578K
- Robert GivenVirginia Beach$157K
- Michael WilliamsVirginia Beach$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.